PT3727460T - Ligandos peptídicos bicíclicos específicos para epha2 - Google Patents
Ligandos peptídicos bicíclicos específicos para epha2Info
- Publication number
- PT3727460T PT3727460T PT188294375T PT18829437T PT3727460T PT 3727460 T PT3727460 T PT 3727460T PT 188294375 T PT188294375 T PT 188294375T PT 18829437 T PT18829437 T PT 18829437T PT 3727460 T PT3727460 T PT 3727460T
- Authority
- PT
- Portugal
- Prior art keywords
- epha2
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1721259.8A GB201721259D0 (en) | 2017-12-19 | 2017-12-19 | Bicyclic peptide ligands specific for EphA2 |
| GBGB1804102.0A GB201804102D0 (en) | 2018-03-14 | 2018-03-14 | Bicycle peptide ligands specific for EphA2 |
| GBGB1818603.1A GB201818603D0 (en) | 2018-11-14 | 2018-11-14 | Bicyclic peptide ligands specific for epha2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3727460T true PT3727460T (pt) | 2022-07-14 |
Family
ID=64902125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT188294375T PT3727460T (pt) | 2017-12-19 | 2018-12-19 | Ligandos peptídicos bicíclicos específicos para epha2 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US11484602B2 (pt) |
| EP (3) | EP3727460B1 (pt) |
| JP (3) | JP7293231B2 (pt) |
| KR (2) | KR20200105840A (pt) |
| CN (2) | CN111741771A (pt) |
| AU (3) | AU2018387417B2 (pt) |
| BR (2) | BR112020012349A2 (pt) |
| CA (2) | CA3086257A1 (pt) |
| DK (1) | DK3727460T3 (pt) |
| ES (1) | ES2922632T3 (pt) |
| HR (1) | HRP20220871T1 (pt) |
| HU (1) | HUE059126T2 (pt) |
| IL (2) | IL275440B2 (pt) |
| LT (1) | LT3727460T (pt) |
| MX (2) | MX2020006482A (pt) |
| PH (1) | PH12020550929A1 (pt) |
| PL (1) | PL3727460T3 (pt) |
| PT (1) | PT3727460T (pt) |
| SG (2) | SG11202005495UA (pt) |
| SI (1) | SI3727460T1 (pt) |
| TW (1) | TWI825046B (pt) |
| WO (2) | WO2019122863A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| CA3095582A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| SG11202110828UA (en) * | 2019-04-02 | 2021-10-28 | Bicycletx Ltd | Bicycle toxin conjugates and uses thereof |
| AU2020269506A1 (en) | 2019-05-09 | 2022-01-06 | Bicycletx Limited | Bicyclic peptide ligands specific for OX40 |
| TW202118770A (zh) * | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| JP2022551607A (ja) * | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| AU2020392890A1 (en) * | 2019-11-27 | 2022-06-02 | Bicycletx Limited | Bicyclic peptide ligands specific for EphA2 and uses thereof |
| MX2022015419A (es) | 2020-06-12 | 2023-03-17 | Bicycletx Ltd | Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2). |
| KR20230074119A (ko) * | 2020-08-03 | 2023-05-26 | 바이사이클티엑스 리미티드 | 펩타이드 기반 링커 |
| EP4274844A1 (en) | 2021-01-08 | 2023-11-15 | BicycleTx Limited | Heterotandem bicyclic peptide complexes |
| JP2024502189A (ja) | 2021-01-11 | 2024-01-17 | バイシクルティーエクス・リミテッド | 癌を処置する方法 |
| EP4349857A1 (en) | 2021-05-25 | 2024-04-10 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| WO2023020485A1 (zh) * | 2021-08-17 | 2023-02-23 | 南京明德新药研发有限公司 | 具有新颖结构的多肽药物偶联物及其应用 |
| TW202320856A (zh) * | 2021-10-14 | 2023-06-01 | 大陸商海思科醫藥集團股份有限公司 | EphA2的雙環肽配體及其綴合物 |
| KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| EP1115888B1 (en) | 1998-09-24 | 2008-03-12 | Indiana University Research and Technology Corporation | Water-soluble luminescent quantum dots and bioconjugates thereof |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| HUE026218T2 (en) | 2002-02-21 | 2016-05-30 | Inst Virology | MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice |
| CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
| EP1852441B1 (en) * | 2002-09-24 | 2012-03-28 | The Burnham Institute | Agents that modulate EPH receptor activity |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| RS54056B1 (en) | 2004-02-06 | 2015-10-30 | Morphosys Ag | ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES |
| CA2505655C (en) | 2004-04-28 | 2013-07-09 | Warren Chan | Stable, water-soluble quantum dot, method of preparation and conjugates thereof |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US7863239B2 (en) | 2005-01-24 | 2011-01-04 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| EP1931645B1 (en) | 2005-10-07 | 2014-07-16 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
| USRE47123E1 (en) * | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
| US7666392B2 (en) | 2006-09-15 | 2010-02-23 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
| SI2526933T1 (sl) | 2006-09-22 | 2015-07-31 | Pharmacyclics, Inc. | Inhibitorji Bruton tirozin kinaze |
| EP3023422A1 (en) | 2007-03-12 | 2016-05-25 | YM BioSciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CA2690449A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| RU2631931C2 (ru) | 2011-10-07 | 2017-09-28 | Байсикл Терапьютикс Лимитед | Модуляция специфичности структурированных белков |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| WO2014164693A2 (en) | 2013-03-12 | 2014-10-09 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| US20140274759A1 (en) * | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| US9868767B2 (en) | 2013-05-23 | 2018-01-16 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
| ES2715379T3 (es) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
| CN106415269B (zh) | 2014-05-08 | 2020-11-27 | 贵州美鑫达医疗科技有限公司 | 直接免疫组织化学测定 |
| CN113861268A (zh) | 2014-05-21 | 2021-12-31 | 恩特拉达治疗学股份有限公司 | 细胞穿透肽及其制备和使用方法 |
| SI3215518T1 (sl) | 2014-10-29 | 2021-08-31 | Bicyclerd Limited | Biciklični peptidni ligandi, značilni za MT1-MMP |
| WO2016171242A1 (ja) | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Ｅｐｈａ２の検出 |
| CN107810190A (zh) * | 2015-04-28 | 2018-03-16 | 洛桑联邦政府综合工科学校（Epfl) | 酶活化因子XII (FXIIa)的新型抑制剂 |
| AU2017232634A1 (en) | 2016-03-16 | 2018-09-13 | Merrimack Pharmaceuticals, Inc | Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) And Related Diagnostics |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109195994A (zh) | 2016-04-22 | 2019-01-11 | 鳄鱼生物科学公司 | 针对cd137的新型双特异性多肽 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| EP3544621A1 (en) | 2016-11-27 | 2019-10-02 | BicycleRD Limited | Methods for treating cancer |
| KR20190126294A (ko) | 2016-12-23 | 2019-11-11 | 바이사이클티엑스 리미티드 | Ｍｔ１－ｍｍｐ에 대한 결합용 펩티드 리간드 |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| EP3615550A1 (en) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP2020529427A (ja) | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| WO2019034868A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF |
| EP3668887A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| WO2019136442A1 (en) | 2018-01-08 | 2019-07-11 | Kleo Pharmaceuticals, Inc. | Cd16a binding agents and uses thereof |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| CA3095582A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| AU2019272575A1 (en) | 2018-05-21 | 2020-12-10 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by NK cells |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| EP3894010A1 (en) | 2018-12-13 | 2021-10-20 | BicycleTX Limited | Bicyclic peptide ligands specific for mt1-mmp |
| US11702482B2 (en) | 2018-12-17 | 2023-07-18 | Revitope Limited | Twin immune cell engager |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| SG11202110828UA (en) | 2019-04-02 | 2021-10-28 | Bicycletx Ltd | Bicycle toxin conjugates and uses thereof |
| AU2020269506A1 (en) | 2019-05-09 | 2022-01-06 | Bicycletx Limited | Bicyclic peptide ligands specific for OX40 |
| TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN114787197A (zh) | 2019-08-13 | 2022-07-22 | 拜斯科技术开发有限公司 | 修饰的多聚双环肽配体 |
| JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| AU2020392890A1 (en) | 2019-11-27 | 2022-06-02 | Bicycletx Limited | Bicyclic peptide ligands specific for EphA2 and uses thereof |
| MX2022015419A (es) | 2020-06-12 | 2023-03-17 | Bicycletx Ltd | Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2). |
| AU2021327130A1 (en) | 2020-08-17 | 2023-03-02 | Bicycletx Limited | Bicycle conjugates specific for Nectin-4 and uses thereof |
| EP4274844A1 (en) | 2021-01-08 | 2023-11-15 | BicycleTx Limited | Heterotandem bicyclic peptide complexes |
| JP2024502189A (ja) | 2021-01-11 | 2024-01-17 | バイシクルティーエクス・リミテッド | 癌を処置する方法 |
-
2018
- 2018-12-11 TW TW107144453A patent/TWI825046B/zh active
- 2018-12-14 US US16/220,685 patent/US11484602B2/en active Active
- 2018-12-19 AU AU2018387417A patent/AU2018387417B2/en active Active
- 2018-12-19 JP JP2020534623A patent/JP7293231B2/ja active Active
- 2018-12-19 SI SI201830718T patent/SI3727460T1/sl unknown
- 2018-12-19 CA CA3086257A patent/CA3086257A1/en active Pending
- 2018-12-19 IL IL275440A patent/IL275440B2/en unknown
- 2018-12-19 HR HRP20220871TT patent/HRP20220871T1/hr unknown
- 2018-12-19 WO PCT/GB2018/053678 patent/WO2019122863A1/en active Application Filing
- 2018-12-19 ES ES18829437T patent/ES2922632T3/es active Active
- 2018-12-19 KR KR1020207019676A patent/KR20200105840A/ko not_active Application Discontinuation
- 2018-12-19 MX MX2020006482A patent/MX2020006482A/es unknown
- 2018-12-19 EP EP18829437.5A patent/EP3727460B1/en active Active
- 2018-12-19 SG SG11202005495UA patent/SG11202005495UA/en unknown
- 2018-12-19 CA CA3085253A patent/CA3085253A1/en active Pending
- 2018-12-19 EP EP18829926.7A patent/EP3727461A1/en active Pending
- 2018-12-19 PT PT188294375T patent/PT3727460T/pt unknown
- 2018-12-19 CN CN201880089757.9A patent/CN111741771A/zh active Pending
- 2018-12-19 CN CN201880089662.7A patent/CN111787955B/zh active Active
- 2018-12-19 HU HUE18829437A patent/HUE059126T2/hu unknown
- 2018-12-19 AU AU2018387418A patent/AU2018387418B2/en active Active
- 2018-12-19 BR BR112020012349-8A patent/BR112020012349A2/pt unknown
- 2018-12-19 SG SG11202005494QA patent/SG11202005494QA/en unknown
- 2018-12-19 EP EP22161978.6A patent/EP4053145B1/en active Active
- 2018-12-19 DK DK18829437.5T patent/DK3727460T3/da active
- 2018-12-19 US US16/771,186 patent/US11696956B2/en active Active
- 2018-12-19 JP JP2020534361A patent/JP7404241B2/ja active Active
- 2018-12-19 PL PL18829437.5T patent/PL3727460T3/pl unknown
- 2018-12-19 MX MX2020006474A patent/MX2020006474A/es unknown
- 2018-12-19 KR KR1020207019675A patent/KR20200105839A/ko active Search and Examination
- 2018-12-19 LT LTEPPCT/GB2018/053675T patent/LT3727460T/lt unknown
- 2018-12-19 BR BR112020012246-7A patent/BR112020012246A2/pt unknown
- 2018-12-19 WO PCT/GB2018/053675 patent/WO2019122860A1/en unknown
-
2020
- 2020-06-17 IL IL275437A patent/IL275437A/en unknown
- 2020-06-17 PH PH12020550929A patent/PH12020550929A1/en unknown
-
2022
- 2022-09-23 US US17/934,896 patent/US11833211B2/en active Active
-
2023
- 2023-05-08 US US18/313,983 patent/US20240000957A1/en active Pending
- 2023-06-07 JP JP2023093890A patent/JP7503689B2/ja active Active
- 2023-11-01 US US18/499,739 patent/US20240189436A1/en active Pending
-
2024
- 2024-04-22 AU AU2024202618A patent/AU2024202618A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275437A (en) | EPHA2-specific bicyclic peptide ligands | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201721265D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201820316D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201721259D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201707734D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201818603D0 (en) | Bicyclic peptide ligands specific for epha2 | |
| GB201720934D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201712693D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201818499D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201815684D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201720941D0 (en) | Bicyclic peptide ligands specific for EPHA3 | |
| GB201720932D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201810321D0 (en) | Peptide ligands for bindingto EphA2 | |
| GB201720928D0 (en) | Bicyclic peptide ligands specific for IL-6 | |
| GB201621574D0 (en) | Bicyclic peptide ligands specific for fapalpha | |
| GB201720933D0 (en) | Bicyclic peptide ligands specific for cathepsin G | |
| GB201720940D0 (en) | Bicyclic peptide ligands specific for PSMA | |
| GB201701834D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| GB201715621D0 (en) | Bicycle peptide ligands specific for EphA2 | |
| GB201720926D0 (en) | Bicyclic peptide ligands specific for chymase | |
| GB201720939D0 (en) | Bicyclic peptide ligands specific for VEGF | |
| GB201720936D0 (en) | Bicyclic peptide ligands specific for TGFbeta | |
| GB201712589D0 (en) | Bicyclic peptide ligands specific for CD137 |